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Background: Melanocytic meningeal tumours are rare extra-axial neoplasms of the nervous system, with only three
reported cases in the cavernous sinus. Herein we describe for the first time the association of ocular melanosis and
multiple intracranial melanocytic meningeal tumours, with the presenting lesion being in the cavernous sinus. The
importance of this association is discussed together with the diagnostic and therapeutic challenges of the case.
Case presentation: A 20-year-old man presented with a left sixth cranial nerve deficit; general examination
documented only congenital melanosis of the homolateral eye. MRI examination showed a space occupying lesion in
the left cavernous sinus, which was followed conservatively for 2 years, until a new space occupying lesion was evident
at the level of the right frontal convexity: both lesions presented with neuroradiological characteristics suggestive of
melanin content.
The frontal convexity lesion was removed: intraoperatively the dura was markedly and diffusely melanotic. Histological
examination documented a melanocytic meningeal tumour, with a proliferative index of 3 %. The patient underwent
3D-Conformal Radiation Therapy on the lesion of the cavernous sinus (total dose 5040 cGy), with initial tumour
reduction. Three years later, due to a symptomatic growth, he underwent partial removal of the lesion in the cavernous
sinus. Histological examination was unchanged. He then received adjuvant Temozolomide with Low Dose Fractionated
Radiation Therapy (LD-FRT). Due to further disease progression cisplatin plus fotemustine were administered,
concomitant with LD-FRT: after two cycles MRI documented significant disease regression. After a period of apparent
disease control, the patient presented with persistent cough and evidence of multiple thoracic metastases, which lead
to his death, seven years after presentation.
Conclusions: Intracranial melanocytic meningeal tumours are challenging lesions, both from a diagnostic and
therapeutic point of view; though rare, the possible association with ocular melanosis should be recognized and might
facilitate an early diagnosis. Surgery remains the best possible option when feasible. In the event of partial resection,
this “benign” disease might be clinically aggressive.
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Melanocytic meningeal tumour is a rare tumour of the
nervous system with approximately 110 reported cases
[1-3]. The possible association with nevus of Ota (also
known as oculo-dermal melanocytosis, which is charac-
terized by the association of ocular and skin or mucosal
melanocytosis) [2,4-9] has been reported previously.* Correspondence: francesco.doglietto@rm.unicatt.it
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reproduction in any medium, provided the orHerein we describe the unique case of the association
of simple ocular melanosis and multiple intracranial
melanocytic meningeal tumours. The diagnostic and
therapeutic challenges of the case are presented together
with a concise literature review.
Case report
Clinical and neuroradiological presentation
A 20 year-old Caucasian male presented to our
department with incomplete left abducens nerve palsy;
neuroradiological examination documented three intra-
cranial space occupying lesions, respectively in the leftral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the superior aspect of the right petrous pyramid
(Figure 1).
He presented with a two year history of diplopia, of
subacute onset, due to a left sixth cranial nerve palsy.
Neurological examination was otherwise normal at the
time; he denied any pain and had no fever. Head CT
scan documented a small space-occupying lesion in the
left cavernous sinus, with well-defined margins and min-
imal contrast enhancement (Figure 2A). Brain MRI con-
firmed the lesion in the posterior compartment of the
left cavernous sinus: its signal behaviour excluded both
fatty and hemorrhagic content of the tumour, excluding
the hypothesis of paramagnetic effect related to hemosi-
derin and blood degradation products (Figure 2). Due to
the high complication rate associate with surgery inside
the cavernous sinus, specifically with respect to a very
high risk of permanent diplopia, his treating doctors
chose to manage him conservatively with low dose corti-
costeroids and surveillance imaging. His diplopia
resolved and a new MRI, three months after the previ-
ous, documented a minimal volume reduction of the left
cavernous sinus mass lesion. Unfortunately the patient
experienced bilateral femoral head necrosis secondary to
corticosteroid use that resulted in discontinuation of
dexamethasone. Three months later a new brain MRI
documented minimal growth of the lesion, which was
confirmed in subsequent examinations and the patient
remained asymptomatic. One year and a half after the
first neuroradiological examination, a repeat brain MRI
documented a contralateral extraaxial lesion, at the level
of the right frontal convexity, with the same radiological
features, characterized by hyper-intensity on un-
enhanced T1-weighted images (Figure 1A); a smaller
extraaxial dural lesion was also evident on the superior
aspect of the right petrous pyramid (Figure 1B).Figure 1 Brain MRI. A) Unenhanced turbo-spin-echo T1-weighted
sagittal image documenting the space occupying lesion at the level
of the left frontal convexity (white arrow).B) Contrast-enhanced fat-
suppressed turbo-spin-echo T1-weighted axial image. MRI
documenting the space occupying lesions at the level of the right
petrous apex (white arrow) and left cavernous sinus (black arrow).At this stage in his care the patient was referred to our
department. Neurological examination documented dip-
lopia only in the extreme left gaze. General examination
documented patches of bluish discoloration of the sclera
at the level of the left eye, which the mother reported to
be congenital (Figure 3); there was no evidence of any
associated facial skin or oral mucosal pigmentation. The
association of the bluish discoloration of the sclera with
the MR signal behaviour (non-hemorrhagic T1-hyper-
intensity) of the intracranial lesions raised the suspicion
of a melanotic tumour, and our opinion was to offer sur-
gery in order to establish definitive diagnosis; it was
decided to remove the frontal lesion, having the least
surgical risk. After a right frontal craniotomy diffuse
blackening of the dura was evident with a darker grading
towards the skull base (Figure 4A); the nodular lesion
appeared to partially infiltrate the arachnoid and was to-
tally removed together with portion of the surrounding
abnormal dura (Figure 4B).
Histology
On haematoxylin and eosin (H&E) staining (Figure 5A –
original magnification: X 300) neoplastic cells appeared
round or spindled, without nuclear atypia and with small
nucleoli. There were occasional mitoses identified (less
than 1x10 HPF). Melanin pigment was present in occa-
sional cells, so we were able to study the nuclear morph-
ology without the need of a melanin bleaching. No
necrosis was observed. After immunohistochemistry with
anti-HMB45 (Figure 5B) and anti Melan-A (Figure 5C)
antibodies, a variable but substantial proportion of neo-
plastic cells appeared immunolabelled (original magnifica-
tion: X 300). After immunohistochemistry with anti
MIB1/Ki67 antibody (Figure 4D) only a low percentage of
neoplastic cells (mean: 3 %) showed nuclear labelling (ori-
ginal magnification: X 250). On the basis of the single
small nucleoli, the relatively low number of mitoses, and
the relatively low Ki67 index, a diagnosis of intermediate
grade melanocytic neoplasm of was made [10]. Moreover,
all the histological features we encountered in our case
but Ki67 were also compatible with a melanocytoma.
Follow-up
Five days after surgery the patient developed a marked
diplopia, pain in the eye and a third cranial nerve palsy.
An urgent CT scan documented a minimal enlargement
of the cavernous sinus lesion (not shown). Corticosteroid
treatment was initiated and three weeks later there was
complete resolution of both pain and cranial nerve palsy.
Corticosteroids were subsequently tapered and discon-
tinued. The patient underwent 3D-Conformal Radiation
Therapy (3D-CRT) of the lesion of the cavernous sinus
(total dose 5040 cGy with a daily dose of 180 cGy), with
an initial tumour reduction. Three years later, due to a
Figure 2 Neuroradiological findings at diagnosis of the lesion inside the cavernous sinus. Contrast enhanced CT (A), documenting the
space occupying lesion in the left cavernous sinus. T1-weighted images documenting the lesion, which is spontaneously hyper-intense (sagittal
view; B – white arrow) and has scarce contrast-enhancement (fat suppressed turbo spin echo T1-weighted axial images after contrast
enhancement; C). Axial source image from MR-angio ruled out a vascular lesion (D). The mass lesion remained hyper-intense on un-enhanced
fat-saturation T1-weighted images (E), strongly hypo-intense on turbo-spin echo fat-saturated T2-weighted images (F), and iso-intense on
gradient echo T2*-weighted images (G).
Doglietto et al. BMC Cancer 2012, 12:220 Page 3 of 6
http://www.biomedcentral.com/1471-2407/12/220symptomatic growth, the patient underwent surgical
debulking of the lesion with resolution of the pre-
operative trigeminal neuralgia and persistence of thirdFigure 3 Melanosis oculi. Black and white picture of the left eye:
the part of the sclera involved by the bluish discoloration has been
left in the original color.cranial nerve palsy. Histological examination of the le-
sion documented features similar to the previously
resected lesion, with a proliferative index of 2 %.
He then received four cycles of adjuvant Temozolo-
mide (150–200 mg/mq/die for 5 days q 28); the third
and fourth cycle were combined with Low Dose Fractio-
nated Radiation Therapy (LD-FRT) 0.4 Gy twice daily
[11,12], with at least a 6-hour inter-fraction interval,
over 5 consecutive days, every 28 days. Subsequent MRI
examinations documented progressive disease: we thenFigure 4 Intraoperative findings at removal of the frontal
lesion. (A.)Diffuse blackening of the dura was evident with an
increasing gradient towards the skull base. (B.)The removed nodule
attached to and surrounded by dark dura.
Figure 5 Histological examination. Haematoxylin and eosin
staining (A - original magnification: X 300) documenting round or
spindled neoplastic cells, with regular nuclei and small nucleoli, with
only occasional mitoses (less than 1x10 HPF); melanin pigment is
evident in occasional cells. Immunohistochemistry with anti-HMB45
(B) and anti Melan-A (C) antibodies documented a variable but
substantial proportion of labelled neoplastic cells (original
magnification: X 300). MIB1/Ki67 immunohistochemistry (D)
documented only a low percentage of labelled neoplastic cells
(mean: 3 %) (original magnification: X 250).
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and fotemustine (40 mg/m2 on days 2, 9, and 16) [13],
concomitant with LD-FRT 0.3 Gy twice daily, with at
least a 6-hour inter-fraction interval [11] on days 1–2,
8–9, and 15–16, every 42, with at least a 6-hour inter-
fraction interval, over 5 consecutive days, every 28 days.
After two cycles MRI documented significant tumour re-
duction and there was a period of apparent tumour con-
trol. Unfortunately, the patient later presented with
persistent cough and hypoxia: a total body CT scan
documented multiple thoracic space occupying lesions,
compatible with metastases. The patient died due to sys-
temic tumour progression seven years after initial
presentation.Discussions
Meningeal melanocytic tumour is a rare tumour of the ner-
vous system, with approximately 110 cases reported since
1972 [1,5]. It originates from melanocytic cells located in the
leptomeninges and is usually a solitary lesion, mostly located
in the posterior fossa and along the cervico-thoracic spinal
cord [14]. To the best of our knowledge, only three case of
melanocytoma of the cavernous sinus have been described
[8,15,16]. According to Brat[10], primary melanocytic neo-
plasms consist of a spectrum of tumours ranging from mela-
nocytomas to malignant melanomas. Melanocytic tumours
with intermediate features (intermediate grade melanocytic
neoplasms) share almost all the histological features of mela-
nocytomas and most of the features of malignant melanomas.Below we identify some factors that render these tumors diffi-
cult to diagnose and their biological behaviour challenging to
predict.
Neuroradiology
On computerized tomography (CT) imaging, melanocy-
tic tumors appear as iso- to slightly hyper-dense lesions
with homogeneous enhancement after contrast media
administration [17,18]. This CT appearance is though
non-specific and similar to that of meningiomas. On
MRI melanocytic tumors are generally reported as iso-
to hyper-intense on T1-weighted images and hypo-
intense on T2-weighted images, with variable degree of
homogeneous enhancement with paramagnetic contrast
injection[17-21]. Unfortunately MRI appearance of mel-
anocytic tumours may vary due to their heterogeneous
content of melanin pigment as well as the presence of
other features, such as intratumoral hemorrhages. Thus,
the classically reported neuro-imaging features could not
reliably distinguish melanocytic tumors from other most
common tumors that may be found in similar dural
locations, i.e., most notably meningioma, schwannoma
and malignant melanoma.[18] However on the basis of
our personal experience (4 pathologically proven, mostly
intraspinal, melanocytic tumors – C. Colosimo, MD, un-
published data, April 2009) the rational analysis of the
MR signal behaviour strongly suggests a melanocytic
tumors when the lesion appears hyper-intense on un-
enhanced T1-weighted images, at the same time show-
ing less intensity on gradient-echo T2*-weighted than on
turbo spin echo T2-weighed images.
Melanocytic tumors and melanosis
Intracranial melanocytic non-metastatic tumors can be
associated with nevus of Ota or oculodermal melanosis
[4]; to the best of our knowledge, the association of mel-
anocytic tumors with simple melanosis oculi [22] has
not been reported: only one case of intracranial melan-
oma associated with melanosis oculi has been previously
described [23]. The importance of this association can-
not be overestimated for the clinical differential diagno-
sis. From an ethiopathogenetic point of view the
presence of congenital melanosis oculi and the intrao-
perative finding of diffuse blackening of the dura are
suggestive of an evolution of a congenital malformation
to cancer. It has indeed been suggested that meningeal
melanosis, a benign excess of melanotic cells in the
leptomeninges, may be a predisposing lesion that could
transform into melanocytic tumor or CNS melanoma
[6,8].
Treatment
Complete surgical resection is the best treatment for
meningeal melanocytic tumors [1]. If not possible,
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suggested [1]. Primary radiotherapy or radiosurgery may
be useful for tumors, which are not amenable to
complete surgical resection, as the cavernous sinus
lesions in our case [24.]
Radiotherapy improves outcomes and a total dose of
50.4 Gy (1.8 Gy per fraction) appears appropriate for
most patients [25]. Radiosurgery may be an alternative
therapeutic option, but specific reports are still limited
[24].
To the best of our knowledge there is also a lack of
data concerning the role of chemotherapy in the treat-
ment of melanocytic tumors [26]. Our decision to pre-
scribe chemotherapy was related to the disease
progression after radiation therapy and incomplete re-
section. Temozolomide, an oral alkylating agent, and
Fotemustine (FTM), a third-generation nitrosourea with
an alkylating cytotoxic activity, were used because they
are able to cross the blood–brain barrier; moreover their
efficacy in treating newly diagnosed glioma or melanoma
brain metastases has been largely demonstrated in com-
bination with radiotherapy.
Rare cases have been reported with leptomeningeal
spread [27-29] transformation to malignant melanoma
[30] and even distant metastases [31-34]. This poten-
tially aggressive behaviour led Cordoba and co-workers
[35] to suggest that melanocytic tumors should be con-
sidered as a borderline malignant tumour. This is indeed
confirmed by the clinical evolution of our patient, who
had an apparently stable disease six years after initial
symptoms and diagnosis, but only after chemotherapy
and radiotherapy; unfortunately, his disease further
progressed, with evidence of systemic metastases that
lead to his death. This supports the use of the term
"melanocytic neoplasm of indeterminate biologic poten-
tial" for tumours that demonstrate intermediate histo-
logical features and might have an aggressive clinical
behavior [36].Conclusions
This is the first reported case of the association of sim-
ple ocular melanosis and intracranial melanocytoma.
Awareness of this association and of the radiological
characteristics of the lesion might help the pre-operative
diagnosis of this rare intracranial tumor. The clinical
course of our patient indeed confirms the relatively ag-
gressive behavior of this tumor.Consent
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